Dennis M. Brown - 01 Aug 2022 Form 4 Insider Report for Kintara Therapeutics, Inc. (KTRA)

Role: Chief Scientific Officer
Signature: /s/ Anthony Scott Praill, attorney-in-fact for Dennis M. Brown
Issuer symbol: KTRA
Transactions as of: 01 Aug 2022
Transactions value $: $0
Form type: 4
Filing time: 03 Aug 2022, 16:30:38 UTC
Previous filing: 07 Jul 2021
Next filing: 06 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KTRA	Common Stock	Award	$0	+240,087	+3521%	$0.000000	246,905	01 Aug 2022	Direct	F1
holding	KTRA	Common Stock						53,750	01 Aug 2022	See footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KTRA	Option (right to buy)	Award	$0	+720,260		$0.000000	720,260	01 Aug 2022	Common Stock	720,260	$0.1757	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person was granted 240,087 restricted stock units, which will be settled in shares of the Issuer's common stock. The restricted stock units vest in 4 equal annual installments beginning on August 1, 2023.
F2	Shares held by Valent Technologies LLC, of which the Reporting Person is the sole member and owner and holds sole voting and dispositive power over its shares.
F3	The option vests as to 25% on August 1, 2023 with the remainder to vest in 36 equal monthly installments thereafter.